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Congenital disorders or birth defects are structural or functional 
anomalies that occur during intrauterine life and can be identified 
prenatally, at birth or later in life. In ~50% of all congenital anomalies, 
no specific cause can be identified.[1]
A teratogen is any substance, agent or process that affects typical 
fetal development, resulting in one or more congenital disorders in 
the fetus. The type of teratogen, its mode of action, the embryonic 
process affected, the genetic predisposition, and the stage of develop­
ment at the time of exposure determine the type and severity of the 
defect. From approximately the 3rd to the 12th week of gestation 
– the period during which differentiation of the major organs and 
systems occurs – the developing embryo is most vulnerable. Known 
teratogens include chemical and pharmaceutical agents such as 
warfarin, thalidomide and alcohol; infectious agents, especially 
rubella, cytomegalovirus and more recently zika virus; ionising 
radiation; and chronic diseases such as diabetes mellitus. Other risk 
factors for birth defects include environmental and personal factors, 
such as age, general health and nutritional status of the mother, or 
intrauterine trauma to the developing fetus.[1,2]
The US Food and Drug Administration (FDA) has a risk category 
classification system to indicate the level of safety of medication in 
pregnancy. Medication is rated from A to D according to the level 
of safety in pregnancy and the level of supporting evidence. For 
example, medication in category A is completely safe in pregnancy, 
while that in category D has proved to have risks in humans and 
should be avoided, unless the benefit for the mother is greater than 
the expected risk. Medication in category X is contraindicated in 
pregnant women or women who may become pregnant, because it is 
known to cause birth defects in animals and humans.[3]
According to the March of Dimes global report on birth defects, 
2006,[4] middle­ and low­income countries have a higher incidence of 
birth defects related to teratogenic medication. This might be owing 
to the regulation of some of these medications being less strict and 
to easy over­the­counter availability. Multiple drug use is common, 
the awareness of the teratogenic potential of certain medications is 
lacking and many women are unaware of their pregnancy during 
the first few weeks.[4] In a South African (SA) study,[5] modelled 
data of genetic causes and an estimate of teratogenic causes showed 
that at least 1 of 15 children born (6.8%) is affected by congenital 
disorders or birth defects. In 19.5% of these cases, teratogens could 
be identified as the causative factor.[5]
Warfarin, a vitamin K inhibitor, is an anticoagulant used in patients 
with an increased risk of thromboembolic events. Indications include 
prosthetic heart valve replacements, some cases of inherited or 
acquired thrombophilias and cardiac arrhythmias, and the treatment 
and prevention of recurrent venous thromboembolism (deep­venous 
thrombosis, pulmonary embolism).[6] In SA, there is a high burden of 
cardiac abnormalities among young women, mostly due to rheumatic 
heart disease, which requires replacement of the damaged valves with 
prosthetic cardiac valves and necessitates life­long anticoagulation 
therapy.[7,8]
When used during pregnancy, warfarin crosses the placental 
barrier and may cause teratogenic complications, including congenital 
defects.[7] Therefore, it is classified as category X in the FDA risk 
classification system. Warfarin­induced embryopathy has a >25% risk 
of fetal abnormalities, especially during weeks 6 ­ 9 of gestation. It 
may also result in central nervous system abnormalities in the 2nd 
and 3rd trimester, possibly due to microhaemorrhages. Fetal warfarin 
syndrome consists of nasal hypoplasia, microphthalmia, hypoplasia 
of the extremities, intrauterine growth retardation, cardiac anomalies, 
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scoliosis, deafness and mental retardation.[10] Furthermore, the risk 
of miscarriages or stillbirths in pregnant women exposed to warfarin 
increases significantly.[7,9,10] Despite these risks, women with chronic 
conditions that necessitate anticoagulation would put their own 
health and life at risk by discontinuing their treatment prior to or 
during a pregnancy. Ideally, they need to plan pregnancies and switch 
to low­molecular­weight heparin (LMWH) before the 6th week of 
pregnancy. In pregnant women at higher risk of thromboembolism, 
such as those with certain mechanical valve replacements or a 
history of thromboembolism when receiving heparin, warfarin 
should be continued in the interest of the mother’s health throughout 
her pregnancy, with replacement by unfractionated heparin or 
LMWH close to delivery.[11­13] A limited number of studies have 
investigated the perspectives and practices of women exposed to 
potentially teratogenic substances to identify high­risk behaviour 
and attitudes that could contribute to congenital abnormalities due 
to teratogenesis.[14­16] International studies have evaluated patients’ 
knowledge and practice with regard to their warfarin treatment in 
terms of side­effects of bleeding, precautions, monitoring of levels 
and emergency management. A few standardised questionnaires 
were verified to test patients’ knowledge regarding these aspects.[17,18] 
No questions were included about the negative effects of warfarin 
use during pregnancy in terms of birth defects. A local study among 
women in Johannesburg using warfarin found that they lacked 
knowledge about the effects of warfarin in general, its effects in 
pregnancy, the need for planned pregnancies and the management 
options available.[19] 
Understanding the challenges and barriers that play a role in 
teratogenesis and addressing these effectively are necessary to 
reduce the incidence of drug­related congenital disorders. Poor 
pregnancy outcomes – presenting as either congenital abnormalities, 
spontaneous abortion or stillbirth – due to the effects of warfarin, are 
seen regularly in SA.[8,19] However, epidemiological data and statistics 
on the exact incidence are not available.
The objective of this study was to determine the knowledge, 
attitudes and practices of women of reproductive potential regarding 
the risk of warfarin in pregnancy. The findings may serve to highlight 
the specific challenges in SA settings and contribute to providing 
recommendations to address this matter.
Methods
In this descriptive study, quantitative data were collected by means 
of a researcher­administered questionnaire. Women of reproductive 
age, defined as between the ages of 15 and 49 years, currently 
receiving warfarin treatment, were included in the study. Participants 
not able to give consent or converse in Sesotho, English or Afrikaans 
were excluded. No pregnant women were included in this study. 
Convenience sampling was used by approaching those who attended 
a specialist anticoagulation clinic in a tertiary hospital. The study 
was explained by the researchers, a written information sheet was 
provided, written consent was obtained and data were collected. 
Data collection was conducted over 8 weeks. This time period was 
selected because of the frequency of follow­up and to allow enough 
time to approach as many clinic attendees as possible. There was no 
limit on the number of participants. Participation was voluntary and 
anonymous.
The questionnaire focused on the following aspects: (i) demo­
graphic information; (ii) details about the initiation of warfarin; 
information about gravidity, parity and pregnancy outcomes; 
relationship status, sexual activity and practice with regard to 
contraception; (iii) patients’ knowledge of contraceptives and the 
teratogenic potential of warfarin; and (iv) attitudes and opinions 
of women regarding various aspects of teratogenic medication and 
methods of information delivery. 
Information pamphlets in a sealed envelope were given to 
participants after completion of the questionnaire. The purpose of 
these pamphlets was to provide education on the teratogenic effects 
of warfarin and advice on appropriate contraceptive measures and 
family planning.
Statistical analysis was done by the Department of Biostatistics, 
University of the Free State (UFS), Bloemfontein, SA. Descriptive 
statistics, i.e. means and standard deviations or medians and 
percentiles for continuous data, and frequencies and percentages for 
categorical data, were calculated.
Ethical approval
Ethical approval for the study was obtained from the Health Sciences 
Research Ethics Committee of the Faculty of Health Sciences, UFS 
(ref. no. HSREC 205/2015) and the Free State Department of Health. 
Results
Demographic information
A total of 101 women participated in the study. The median age of 
participants was 34 (range 18 ­ 49) years. The participants resided in 
urban and rural areas of Free State Province. Their information with 
regard to highest level of education, relationship status, employment 
and home language is summarised in Table 1. Most participants 
(n=65/98; 66.3%) received secondary education to Grade 10 ­ 12 level. 
Fifty­one women (50.5%) indicated that they were in a casual or 
full­time relationship. In approximately one­third of participants 
(n=33; 32.7%), their sole source of income was government subsidies. 
Sesotho was the home language of 63 participants (62.4%).
Practice
Table 1. Participants’ demographic information regarding level 
of education, relationship status, employment, income and home 
language
Variable n (%)
Level of education (n=98)
Grade 5 or lower 10 (10.2)
Grade 8 or 9 12 (12.2)
Grade 10 ­ 12 65 (66.3)
Tertiary education 11 (11.2)
Relationship status (N=101)
Single, separated or widowed 50 (49.5)
In a casual or full­time relationship 51 (50.5)
Employment status (N=101)
Unemployed
Casually employed
Permanently employed
76 (75.3)
17 (16.8)
8 (7.9)
Main source of income (N=101)
Government subsidy only
Own income
Partner’s income
Family support
33 (32.7)
26 (25.7)
22 (21.8)
20 (19.8)
Home language (N=101)
Sesotho 63 (62.4)
Afrikaans 16 (15.8)
Setswana 13 (12.9)
isiXhosa/isiZulu 7 (6.9)
English 2 (2.0)
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The most common indications for warfarin 
use were heart valve replacements (n=44; 
43.6%) and deep­venous thrombosis (n=43; 
42.6%). The duration of treatment ranged 
from 1 week to 32 years, with a median 
duration of 4 years. In 37 participants 
(36.6%), warfarin was initiated by adult 
cardiology departments at tertiary level, and 
in 25 cases (24.8%), by general medicine 
departments at primary care level. Table 2 
provides the reason for treatment and level 
of care where treatment was initiated.
Participants were asked whether they had 
a pregnancy test prior to the initiation of 
warfarin; 32 (31.7%) indicated that they 
were tested and 36 (35.6%) that no preg­
nancy test was done. Nineteen partici pants 
(18.8%) were unsure, while in 14 (13.9%) 
doing a pregnancy test would not have 
been applicable (3 women were initiated on 
treatment during pregnancy, 5 were post­
partum, 5 were ˂15 years of age, and 1 had 
undergone tubal ligation). Approximately 
two­thirds of women (61.3%) admitted to 
taking additional chronic medication, of 
which the most common were unspecified 
‘cardiac’ drugs, antiretroviral and antihyper­
tensive agents. 
With regard to sexual activity, 25 partici­
pants (24.8%) were not sexually active at 
the time of the study, with the remainder 
(n=76; 75.2%) indicating that they were in 
a sexual relationship. Of the sexually active 
participants, 15 (19.7%) were not using any 
contraception and another 15 (19.8%) were 
using male condoms only.
When asked about single v. double contra­
ception, 16 of the 70 women (22.9%) who 
used contraception (some used contra­
ception despite not being sexually active 
at the time of the study) indicated that 
they were using two different methods of 
contraception. Eight of the participants 
(11.4%) using contraception admitted to 
not using it regularly. Only 17 of all the 
participants (17.0%) reported ever having 
asked for contraceptive advice, mostly from 
the nursing sister at the local clinic. A third of 
the participants (n=32/100; 32.0%) indicated 
that they were planning future pregnancies.
Outcomes of pregnancies
Among the 101 women, 87 (86.1%) had 
been pregnant at least once. A total of 
209 pregnancies were reported by these 
participants, of which 110 (52.6%) were 
planned. Twenty­six of these 87 women 
(29.9%) had used warfarin during ≥1 of 
their pregnancies. The outcomes of 208 of 
the pregnancies, as reported by the mothers, 
are indicated in Fig. 1. One live birth was 
excluded from these calculations, as the 
relevant child was diagnosed with fetal 
warfarin syndrome by our department. In all 
the other cases, pregnancy outcomes were 
reported by the participants and cases of 
fetal warfarin syndrome in this group could 
not be excluded, as it was not known if the 
children had been specifically evaluated by 
a geneticist or paediatrician for warfarin­
related birth defects.
Knowledge
Fewer than half of the women (n=47; 46.5%) 
indicated that they had been informed about 
the effects of warfarin in pregnancy. Of these, 
Table 2. Details of initiation of warfarin
Initiation of warfarin n (%)
Indication for warfarin use
Heart valve replacement 44 (43.6)
Deep­venous thrombosis 43 (42.6)
Pulmonary embolism 8 (7.9)
Arrhythmias 2 (2.0)
Other emboli (central nervous system, cardiac) 3 (3.0)
Uncertain 1 (1.0)
Treatment initiated by
Adult cardiologist 40 (39.6)
Paediatric cardiologist 8 (7.9)
General medical practitioner 37 (36.6)
Obstetrician/gynaecologist 9 (8.9)
Rheumatologist 2 (2.0)
Neurologist 2 (2.0)
Endocrinologist 1 (1.0)
Surgeon 1 (1.0)
Pulmonologist 1 (1.0)
Level of care
Primary 26 (25.7)
Secondary 17 (16.8)
Tertiary/academic 58 (57.3)
Figure 1 
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Pregnancy outcomes (n=208)*
No (n=169)
Live birth  (n=20; 51.3%)
Stillbirth  (n=4; 10.2%)
Miscarriage  (n=15; 38.5%)
Live birth   (n=136; 80.5%)
Stillbirth   (n=9; 5.3%)
Miscarriage   (n=17; 10.0%)
Termination   (n=3; 1.8%)
Neonatal death  (n=2; 1.2%)
Ectopic   (n=2; 1.2%)
Warfarin used during
pregnancy?
Yes (n=39)
Fig. 1. Pregnancy outcomes in warfarin-exposed v. warfarin-unexposed pregnancies. (*Of the 
101 partici pants, 87 had been pregnant before, with 209 pregnancies collectively among them. One 
pregnancy was excluded from the calculations, as the infant was diagnosed with fetal warfarin 
syndrome.)
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24 (52.2%) received this information from their doctor and 18 (39.1%) 
from the nursing sister at the clinic. 
The majority of participants (n=89/100; 89%) had no concept or 
understanding of the term birth defects. An open­ended question 
about substances that participants might consider to be harmful to 
a fetus during pregnancy, elicited truly teratogenic substances (e.g. 
alcohol was listed by 65 participants), but also inappropriate substances 
or exposures (such as a lack of exercise, stress, lifting heavy objects and 
using laxatives).
Participants’ concept of risk was evaluated. Three different ways of 
stating the same risk was presented; they had to indicate the highest 
risk, which included: (i) 10%; (ii) 1 of 10; and (iii) 10 of 100. They 
could also indicate whether all these statements were the same. Option 
1 was selected by 39 (38.6%), option 2 by 10 (9.9%) and option 3 
by 22 (21.8%) participants. Fewer than one­third (n=30; 29.7%) of 
participants indicated correctly that all these expressions of risk were 
the same. 
When asked about the procedure to follow if a pregnancy were 
desired, the majority (n=91; 90.1%) indicated correctly that they should 
plan the pregnancy and discuss it with the doctor or nursing sister. 
Four women (4.0%) thought they should discontinue their warfarin 
and 6 (5.9%) that they should discontinue their contraceptives. More 
than 45% of the women (n=47; 46.5%) were of the opinion that the 
period of highest risk for congenital abnormalities in a pregnancy does 
not differ between trimesters. Of those who did indicate a specific 
trimester (n=54), 39 (72.2%) thought that the first 3 months have the 
highest risk, while 5 (9.3%) regarded the second trimester as having the 
highest risk. The remaining participants (n=10; 18.5%) either indicated 
the last trimester (n=9) or were uncertain (n=1).
The chance of warfarin causing abnormalities in the baby when 
administered during pregnancy, was estimated as 5% by 30 partici­
pants (29.7%), 30% by 17 (16.8%), 90% by 22 (21.8%), and 100% by 
29 (28.7%), while 3 (3.0%) were unsure. The women’s knowledge of 
the specific congenital abnormalities associated with warfarin was 
evaluated. These results are shown in Table 3. The majority of women 
either thought that these specific abnormalities could not be caused 
by warfarin, or were uncertain.
Among the women planning further pregnancies (n=32), know­
ledge regarding the abovementioned congenital abnormalities was 
better compared with the group as a whole, with 17 (53.1%) stating 
correctly that warfarin could cause brain abnormalities, 9 (28.1%) 
skeletal abnormalities and 11 (34.4%) nasal abnormalities. 
The participants’ knowledge of the reliability of contraceptive 
methods in general was assessed by asking which method has the 
lowest chance of a pregnancy. Oral or injectable contraceptives were 
indicated by 61 participants (60.4%), male and female condoms by 
26 (25.7%) and 11 (10.9%), respectively, and checking the calendar 
by 3 (3.0%).
Attitudes
Fifty­two participants (51.5%) felt that they did not have sufficient 
information about warfarin in pregnancy, while 38 (37.6%) indicated 
that they were satisfied with the amount of information they had, and 
11 (10.9%) were unsure. Those who indicated that they did not have 
sufficient information were asked to provide reasons. According to 27 
(52.9%), they were ‘never given the information’, 12 (23.5%) indicated 
that they ‘did not ask for information’ and 4 (7.8%) that they ‘did 
not understand the explanation’. Three participants (5.9%) said they 
‘were given information, but forgot because no written material was 
provided’, 2 (3.9%) ‘did not understand the language the information 
was given in’, and the remaining 3 (5.9%) each gave another reason.
More than two­thirds of women (n=69; 68.3%) felt that it was 
their doctors’ responsibility to inform them regarding the effects of 
medication in pregnancy. Twelve (11.9%) felt it was the responsibility 
of the clinic nurse and 1 participant (1.0%) thought it should be 
the pharmacist’s role. Nineteen women (18.8%) indicated that all of 
these healthcare providers should inform patients about the effects of 
medication taken during pregnancy. Most participants (n=81; 80.2%) 
indicated that they would prefer more information about the risks of 
their medication in pregnancy. The preferred method of information 
transfer was assessed (Table 4). The majority of participants (n=74; 
73.3%) preferred a counselling session that is translated into their 
home language.
Discussion
Practice
Counselling with regard to the potential risks in pregnancy, appropriate 
contraceptive measures and performing a pregnancy test should form 
an important part of initiating any potentially teratogenic medication 
in a woman of reproductive age. Re­evaluating contraceptive options 
and planning of a pregnancy should ideally form part of every follow­
up consultation in this group of patients, and care should be taken 
to counsel all girls at the onset of puberty, who had been initiated 
on teratogenic medication in childhood.[12] It would be beneficial to 
have a family planning nurse at specialist follow­up clinics, who also 
understands the complexity of the consultations. For instance, in 
patients with certain cardiac conditions (such as valve replacements), 
not only is it important to keep the risks of teratogenesis due to the 
medication in mind, but also the potential risks for the mother’s health 
during pregnancy and delivery;[11] therefore, preventing an unplanned 
or unwanted pregnancy is all the more important. 
Among our study participants, all levels of care, from primary­ to 
academic­level services, as well as professionals in various fields of 
specialty, were involved in the initiation of warfarin therapy. This 
emphasises that all healthcare providers involved in different levels of 
care and in different fields in medicine should be equipped to deal with 
women of reproductive potential who receive teratogenic medication, 
or be aware of the need for counselling. 
Only a third of participants (n=32; 36.8%) in whom a pregnancy test 
prior to initiation would have been indicated, did report it being done. 
Recall by participants could have been deficient, although further 
exploration of this observation was beyond the scope of the study.
The number of participants admitting to being sexually active at 
the time of the study (n=76; 75.2%) was higher than the number 
indicating that they were in a casual or full­time relationship 
(n=51; 50.5%). This finding could be attributed to short­term 
sexual encounters that might have resulted in a high risk for 
unplanned pregnancies and sexually transmitted diseases if effective 
contraceptive practices were not adhered to. Contraceptive practices 
were poor, with 30 women (39.5%) admitting to be sexually active 
Table 3. Participants’ knowledge about specific abnormalities caused by warfarin (N=101)
Question Yes, n (%) No, n (%) Unsure, n (%)
Can warfarin cause brain abnormalities? 8 (7.9) 32 (31.7) 61 (60.4)
Can warfarin cause abnormalities of the bony structure or skeleton? 9 (8.9) 43 (42.5) 49 (48.5)
Can warfarin cause abnormalities of the baby’s nose, with breathing problems? 8 (7.9) 42 (41.6) 51 (50.5)
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but either not using any contraception or using only male condoms. 
Additionally, contraception was not used regularly. Effective family­
planning strategies are important to prevent unplanned pregnancies 
and reduce the risk of babies born with congenital abnormalities. 
Women who understand the risks and options available will be 
empowered to implement better contraceptive practices.
Guidelines for managing pregnant patients on anticoagulants for 
specific indications are available locally and inter nationally.[11­13,20] The 
World Health Organization (WHO) medi cal eligibility criteria for 
contraceptive use provide specific recommendations for contraceptives 
in women with chronic medical conditions.[21]
Outcomes of pregnancies
The live birth rate in the pregnancies of women exposed to warfarin 
was much lower (n=20/39; 51.3%) compared with those not exposed 
to warfarin (n=136/169; 80.5%). Conversely, the rate of pregnancy 
loss was much higher in the warfarin­exposed pregnancies due to 
stillbirths and miscarriages. 
According to international figures, ~70% of pregnancies exposed to 
warfarin are expected to result in a normal infant, with the remaining 
30% of pregnancies ending in a miscarriage, stillbirth or fetal 
abnormalities.[10] A Johannesburg study of women with heart valve 
replacements, who were receiving warfarin, had poor fetal outcomes 
in 55.2% of pregnancies.[19] In another study in KwaZulu­Natal, the 
findings were similar to international figures, with 67% of warfarin­
exposed pregnancies resulting in live births.[7] Numerous factors can 
potentially further contribute to the poorer pregnancy outcomes 
in our study population. These factors include socioeconomic 
circumstances, the high burden of infective diseases, inadequate 
healthcare services for this high­risk group, unequal access to care, 
and patient factors, such as late presentation to healthcare services 
and language barriers.[22­27]
Knowledge
The level of education was high in this population group, with 
76 women (77.6%) having attained at least Grade 10. This level 
of education was not in agreement with the participants’ poor 
understanding of basic terminology and mathematics, which was 
needed to grasp the concept of teratogenesis. Birth defects is a 
layman’s term commonly used in medical practice during the 
counselling of patients. In the group of women interviewed, ~90% 
had no understanding of its meaning. Risk is usually expressed as a 
percentage or a number, e.g. out of 100 or 1 000. Most of the participants 
(n=71; 70.3%) had no understanding of these expressions of risk 
and how to interpret them. Risk is known to be a difficult concept 
to understand and requires a fair amount of skill and experience to 
convey during a counselling session.[28]
Knowledge regarding the differences in periods of risk for 
congenital anomalies during a pregnancy was poor. Most participants 
were also not aware of the specific congenital abnormalities associated 
with warfarin. This lack of knowledge and understanding about the 
potentially serious risks of warfarin in pregnancy does not provide a 
good platform for informed decisions. Their insufficient knowledge 
could be considered a contributing factor to the poor contraceptive 
practices and family planning choices that have been observed in this 
group. A positive observation was that the knowledge of the subgroup 
of women who were planning a future pregnancy was much better 
than that of the group as a whole.
The risk of having a child affected by a birth defect due to the 
use of warfarin during pregnancy was either overestimated (n=51; 
50.5%) or underestimated (n=30; 29.7%). One explanation could be 
the participants’ poor concept of risk. International studies found that 
healthcare providers and the general public cannot make an accurate 
estimate of the risks of common medications and substances used 
during pregnancy.[14,15,29]
Attitudes
We noted a general attitude among the participants of expecting 
information to be provided without explicitly asking for it. This 
observation was reflected by the low percentage of women having 
asked for contraceptive advice, and also by the explanations or reasons 
provided for their lack of information on the effects of warfarin in 
pregnancy. Close to 70% of participants felt that the attending doctor 
should be responsible for providing this information, suggesting 
that most participants had a passive attitude rather than active 
participation in the process of obtaining information.
The majority of women (n=81; 80.2%) indicated that they would 
prefer to be more informed about the teratogenic effects of warfarin 
in pregnancy. It demonstrates their receptiveness to counselling and 
advice, and opens a window of opportunity to address these issues. 
Using the correct method of information delivery for the specific 
target group of patients is very important. The women in our study 
preferred personal counselling sessions – similar to the opinions 
of women in a US study.[30] More than 70% of our participants 
indicated that they would prefer the counselling to be conducted in 
or translated to their home language. 
As part of the study, an information pamphlet was designed, which 
was distributed to the women after completion of the questionnaire. 
It included information on the risks of warfarin in pregnancy, 
alternatives during pregnancy, contraceptive options and contact 
details for preconception counselling if a pregnancy was desired. 
Conclusions and recommendations
Patient­related challenges that were identified in this study include 
language barriers, poor understanding of basic terminology and 
mathematics, poor contraceptive and family planning practices, 
lack of knowledge regarding the risks of warfarin in pregnancy and 
passive attitudes towards obtaining information. 
Systemic factors were not evaluated, but problems that came to 
light were the lack of sufficiently skilled counsellors at specialist 
clinics, lack of contraceptive counselling as part of routine follow­up 
and lack of interdisciplinary involvement in the care of these high­
risk patients. 
To decrease the incidence of the potentially avoidable congenital 
abnormalities and pregnancy losses due to the teratogenic effect 
of certain medications, these challenges need to be addressed. 
The matter should be approached with the utmost sensitivity, as 
there are severe, potentially life­threatening risks to the woman 
if she discontinues her chronic medication prior to or during 
a pregnancy, without starting an alternative treatment plan and 
sufficient monitoring. 
Awareness of the teratogenic potential of specific chronic medications 
Table 4. Participants’ preference for delivery of information 
regarding the use of warfarin during pregnancy (N=101)
Preferred method of information delivery n (%)
Posters at the clinic 6 (5.9)
Information leaflets in English 2 (1.9)
Information leaflets in home language 9 (8.9)
Counselling session in English 5 (4.9)
Counselling session translated to home language 74 (73.3)
Pharmacist explaining before handing out medication 4 (3.9)
Warnings printed on medication box 4 (3.9)
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among all levels of healthcare providers, patients and the public 
should be improved. We recommend further research to explore 
the practice, knowledge and attitudes of healthcare professionals 
involved in initiating women of reproductive age on teratogenic 
medication. Healthcare providers involved in the care of these 
women, including nursing staff and pharmacists, have to be aware 
of and skilled in communicating basic concepts, including risks and 
uncertainties. This approach requires special training that preferably 
should commence at undergraduate level. An adequate number of 
translators and/or healthcare providers fluent in local languages is 
necessary to overcome the language barriers in the SA healthcare 
system. Counselling should be done in or translated to the patient’s 
home language where possible, and written material should be 
available in local languages. This would assist in recall of important 
aspects of the counselling session and can be kept as a reference. 
Specific measures should be put in place to provide improved multi­
disciplinary care to women of reproductive age who receive potentially 
teratogenic chronic medication. Clinics where these women are followed 
up should have contraceptive counselling and family­planning special­
ists available for consultation. A system could be put in place where 
potentially teratogenic medication is issued by the pharmacy only 
after proof of contraceptive counselling/pregnancy testing has been 
provided. Timely preconception referral to high­risk antenatal clinics 
should be arranged for these women who desire a pregnancy, to plan 
alternative treatment strategies during pregnancy and to optimise the 
mother’s health prior to conception.[31] Obstetricians, clinical geneti­
cists and, where appropriate, cardiologists and haematologists should 
form part of the team at the antenatal clinic.
Adjusting practices and following a person­centred care approach 
tailored to the needs of our local population, can contribute to reducing 
the incidence of birth defects and improving the health of mothers with 
chronic diseases. 
Study limitations
This study was conducted at a single tertiary centre with a specific 
population profile and included a small sample of participants. The 
results are not necessarily applicable to other populations at different 
levels of care or with diverse demographic profiles. Further studies 
are recommended on a larger population, between multiple centres 
and among women exposed to various other teratogenic substances.
The women in the study relied on their own recollection when 
formulating answers that were not confirmed by medical records. 
Therefore, their feedback might not be an accurate reflection of the 
services that they received or the outcomes of their pregnancies.
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